6-APB Pellets – 130mg
€ 24,75 – € 737,50Price range: € 24,75 through € 737,50
6-APB Pellets 130mg are described as compressed research pellets containing 6-APB hydrochloride, a substituted aminopropylbenzofuran compound.
The supplied chemical name is 1-(benzofuran-6-yl)propan-2-amine, also known as 6-(2-aminopropyl)benzofuran.
The reported presentation consists of compressed pellets with a nominal 130 mg of 6-APB HCl per unit.
The named neutral compound has molecular formula C11H13NO and molecular weight approximately 175.23 g/mol. The corresponding anhydrous hydrochloride has composition C11H14ClNO and molecular weight approximately 211.69 g/mol.
Relevant scientific contexts include chemical identity assessment, chromatographic characterization, structural comparison, and evaluation of finished-pellet composition.
The stated 130 mg content is a label claim and has not been verified by a finished-product assay.
The source also claims ingredient purity of at least 98%, independent testing, batch traceability, and supporting Certificates of Analysis.
No actual batch-specific analytical records were supplied.
Pellet excipients, content uniformity, hydrochloride identity, stereochemical composition, and storage stability remain unverified.
The pellets are not established as certified reference materials or validated quantitative calibration standards.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
6-APB Pellets 130mg – Benzofuran Research Material
6-APB Pellets 130mg – Product Overview
6-APB Pellets 130mg is the supplied catalog designation for a research pellet product described as containing 6-APB hydrochloride.
6-APB belongs to the substituted aminopropylbenzofuran family of synthetic compounds.
Its named molecular structure contains a fused benzofuran ring system and an aminopropyl side chain attached at the 6-position.
The supplied source describes compressed pellets with a nominal ingredient content of 130 mg per unit.
The stated scientific contexts include chemical identity assessment, chromatographic characterization, structural comparison, and evaluation of finished-pellet composition.
These research contexts should not be confused with verified analytical performance of the actual product batch.
The source describes the ingredient as high purity and refers to independent analytical verification.
However, no actual laboratory report, Certificate of Analysis, finished-pellet assay, or batch record was supplied.
The stated 130 mg per pellet therefore remains a nominal label claim.
The reported ingredient purity, pellet composition, content uniformity, and stability also require verification.
The pellets are not established as certified reference materials, validated quantitative calibrators, or approved pharmaceutical products.
Chemical Identity & Classification
The supplied source identifies the active compound as 6-APB, expanded as 6-(2-aminopropyl)benzofuran.
The named structure belongs to the substituted aminopropylbenzofuran family.
The compound contains a fused benzofuran ring system and an aminopropyl side chain attached at the 6-position.
The supplied chemical information includes:
- Product designation: 6-APB Pellets 130mg
- Chemical name: 1-(Benzofuran-6-yl)propan-2-amine
- Common abbreviation: 6-APB
- Reported ingredient form: Hydrochloride
- CAS Registry Number supplied for this listing: 286834-84-2
- Neutral molecular formula: C11H13NO
- Neutral molecular weight: Approximately 175.23 g/mol
- Anhydrous hydrochloride composition: C11H14ClNO
- Calculated anhydrous hydrochloride molecular weight: Approximately 211.69 g/mol
- Chemical classification: Substituted aminopropylbenzofuran
- Reported presentation: Compressed pellets
- Nominal ingredient content: 130 mg per pellet
- Intended designation: Research Use Only
The neutral molecular formula and molecular weight describe the freebase form of the named compound.
They do not describe the complete hydrochloride ingredient or finished-pellet formulation.
The source identifies the ingredient as 6-APB HCl, but no batch-specific analytical record was supplied confirming the salt form.
The supplied CAS number has not been independently verified against an authoritative registry.
The earlier 6-APB Powder brief separately reported CAS number 286834-85-3.
These different CAS assignments should not be treated as interchangeable without confirming the associated chemical forms.
The source also does not identify the stereochemical composition of the material.
Because the named structure contains a potentially stereogenic center, stereochemical identity may be relevant to definitive characterization.
Researchers may consult PubChem for public chemical-reference information, ensuring that any selected record corresponds to the actual molecular structure, stereochemistry, and chemical form.
Chemical & Physical Characteristics
The supplied source describes the finished product as compressed pellets containing 6-APB hydrochloride.
No actual product-specific physical inspection report, image verification, or batch appearance record was supplied.
The reported pellet presentation therefore remains a supplier-provided description.
The named compound contains a benzofuran ring system with an aminopropyl substituent at the 6-position.
These structural features distinguish it from related benzofuran compounds with different substitution positions or side-chain arrangements.
In particular, 6-APB and 5-APB are positional isomers.
They share the same neutral molecular formula but differ in the attachment position of the aminopropyl side chain.
The source describes the material as suitable for analytical investigation of dissolution, solubility, and stability.
However, no finished-product dissolution measurements, extraction-recovery records, or validated stability studies were supplied.
The source does not establish the physical form of the ingredient within the pellet.
It also does not provide a verified pellet composition, excipient profile, compression specification, or disintegration characteristics.
The source does not establish the presence or absence of residual solvents, related benzofuran impurities, or other formulation components.
Consequently, no definitive claim is made about the physical behavior, analytical recovery, or composition of the actual finished-pellet batch.
Purity & Analytical Verification
The supplied source claims ingredient purity of at least 98% by HPLC.
It also refers to identity confirmation using mass spectrometry and NMR spectroscopy.
No actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, impurity profile, or independent laboratory report was supplied.
The claimed ingredient purity therefore remains unverified.
For 6-APB Pellets 130mg, ingredient purity must be distinguished from finished-pellet content.
A high-purity 6-APB ingredient does not independently establish that each pellet contains 130 mg of the hydrochloride.
It also does not demonstrate pellet-to-pellet content uniformity.
The source refers to LC-MS/MS, HPLC, UV analysis, and spectroscopic comparison as relevant analytical contexts.
However, no finished-product assay, content-uniformity study, or validated analytical method was supplied.
The source additionally claims consistent pellet weight and dissolution performance.
Neither a pellet-weight specification nor a dissolution claim establishes the actual 6-APB content without appropriate supporting analytical results.
No certified reference-material documentation, assigned reference value, measurement-uncertainty statement, or metrological traceability record was provided.
The pellets should therefore not be described as certified quantitative reference standards.
Any definitive claims about ingredient purity, pellet content, impurity levels, or quantitative reference suitability require supporting analytical records.
Quality Control & Batch Integrity
The source refers to third-party testing, batch-specific tracking, complete documentation, and controlled production conditions. 6-APB Pellets 130mg
It also claims pellet-weight variation of approximately ±2% and consistent dissolution performance.
These are supplier-provided quality-assurance claims.
No actual third-party report, batch record, manufacturing audit, weight-variation dataset, dissolution study, or certification was supplied.
The claims therefore remain unverified.
For finished pellets, relevant documentation may include verified ingredient identity, confirmed salt form, positional-isomer identity, stereochemical composition where available, pellet-content assay, content uniformity, excipient information, batch number, analytical findings, receipt date, and available storage history.
The source does not establish independently verified ingredient purity, finished-pellet content, residual-solvent limits, or batch-to-batch equivalence.
For 6-APB Pellets 130mg, the distinction between source-reported specifications and independently verified analytical findings is particularly important.
The Research Use Only designation describes intended positioning but does not independently demonstrate quality, traceability, or validated analytical performance.
Claims concerning independent verification, manufacturing controls, pellet-weight consistency, impurity limits, and batch integrity should be supported by actual records.
Safety, Handling & Laboratory Precautions
6-APB is a substituted aminopropylbenzofuran associated with stimulant-class and serotonergic pharmacological concerns.
Related compounds may present significant cardiovascular, neurological, and other toxicological hazards. 6-APB Pellets 130mg
The supplied source does not provide a complete product-specific toxicological assessment or verified Safety Data Sheet.
Laboratory personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Relevant precautions include restricted access, appropriate protective equipment, contamination prevention, accidental-exposure procedures, and chemical-waste management.
The compressed pellet presentation does not eliminate the need to verify ingredient identity and finished-product composition.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual pellet content, ingredient purity, and impurity profile have not been independently confirmed, laboratory records should clearly distinguish supplier-provided specifications from verified findings.
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The supplied source describes compressed pellets supplied in resealable packaging.
No actual packaging specification, container-validation report, or shipment-condition record was supplied. 6-APB Pellets 130mg
The source recommends storage in a cool, dry environment protected from light and moisture.
It also suggests refrigeration at approximately 2–8°C.
No validated finished-product stability study was supplied to establish that temperature range as a verified requirement or to support a particular shelf life.
For 6-APB Pellets 130mg, laboratory inventory records should preserve the product designation, nominal ingredient content, any available batch identifier, receipt details, and relevant storage observations.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional procedures.
The source does not establish validated long-term stability of the 6-APB ingredient or the complete pellet formulation under the suggested storage conditions.
Intended Research Use & Market Positioning
The supplied scientific context places 6-APB within analytical research involving substituted benzofuran chemical identity, structural characterization, and comparative compound profiling.
The fused benzofuran ring system and aminopropyl side chain at the 6-position provide distinguishing structural features relevant to chemical identification.
However, the actual finished-pellet composition, hydrochloride identity, positional-isomer identity, and quantitative ingredient content have not been independently established.
The source describes interest in chromatographic characterization, spectroscopic identification, and analytical comparison with related compounds. 6-APB Pellets 130mg
No product-specific analytical validation, finished-pellet assay, or stability study was supplied.
The Raw Lab Chems catalog identifies 6-APB Pellets 130mg as the product listing discussed here.
For related catalog context, the supplied source also identifies 6-APB Capsules 100mg and 5-MAPB Powder.
6-APB Capsules 100mg represents a different finished-product presentation with its own nominal content and formulation requirements.
5-MAPB is an N-methylated benzofuran analog and should not be treated as chemically identical to 6-APB.
The supplied information does not establish equivalent ingredient purity, chemical identity, formulation, or analytical performance across these products.
These catalog references should not be interpreted as evidence of certified reference-material status or validated quantitative equivalence.
Ordering, Availability & Fulfillment
The supplied source describes international shipping, tracking, protective containment, and supporting customs documentation. 6-APB Pellets 130mg
No current inventory record, carrier agreement, shipment authorization, or verified delivery information was supplied.
The source also claims compliance with IATA and DOT requirements.
No applicable dangerous-goods classification, shipping declaration, or transport-compliance documentation was provided to substantiate those claims.
Consequently, no availability, delivery-time, customs-clearance, or transportation-compliance guarantee is asserted.
6-APB may be subject to controlled-substance, analogue, pharmaceutical, or other chemical regulations depending on the jurisdiction.
Institutional acquisition, possession, transportation, importation, and exportation must be assessed under applicable laws.
Research-only labeling does not establish a legal exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
6-APB is a substituted aminopropylbenzofuran whose possession, acquisition, transfer, transportation, importation, exportation, and laboratory investigation may be restricted or prohibited depending on the jurisdiction. 6-APB Pellets 130mg
The supplied information does not establish universal legal status or regulatory authorization.
Institutions remain responsible for determining applicable legal requirements and obtaining any necessary permissions.
No medical approval, consumer-use authorization, or regulatory exemption is implied by this description.
| Quantity (pellets) |
5 ,10 ,25 ,50 ,100 ,250 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.